GT Biopharma, Inc. Uncategorized Contracts & Agreements

20 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Investigator Initiated Clinical Trial Agreement, dated as of November 18, 2024, by and between GT Biopharma, Inc. and the Regents of the University of Minnesota
GT Biopharma, Inc.
Biotechnology
MN
2024
Sponsored Research Agreement with the Regents of the University of Minnesota dated May 20, 2024
GT Biopharma, Inc.
Biotechnology
2024
Description of the Registrants Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended
GT Biopharma, Inc.
Biotechnology
2023
Research Agreement with Regents of the University of Minnesota, dated June 16, 2021
GT Biopharma, Inc.
Biotechnology
2022
SETTLEMENTAGREEMENT
GT Biopharma, Inc.
Biotechnology
NY
2020
Consultant Agreement with Michael Handelman, dated November 13, 2020
GT Biopharma, Inc.
Biotechnology
DE
2020
Steve Weldon Letter of Resignation, dated November 11, 2020
GT Biopharma, Inc.
Biotechnology
2020
Clinical Trial Agreement with University of Minnesota
GT Biopharma, Inc.
Biotechnology
MN
2020
Consultant Agreement, dated as of February 14, 2018, between the Company and Mr. Cataldo
GT Biopharma, Inc.
Biotechnology
DE
2018
Amended Preferred Conversion Agreement
GT Biopharma, Inc.
Biotechnology
2017
Preferred Conversion Agreement
GT Biopharma, Inc.
Biotechnology
NY
2017
EMPLOYMENTAGREEMENT
GT Biopharma, Inc.
Biotechnology
DE
2017
RESEARCH AGREEMENT
GT Biopharma, Inc.
Biotechnology
2015
[OXIS LETTERHEAD]
GT Biopharma, Inc.
Biotechnology
2009
SECURED PROMISSORYNOTE
GT Biopharma, Inc.
Biotechnology
DE
2008
ASSETPURCHASE AGREEMENT
GT Biopharma, Inc.
Biotechnology
DE
2008
AGREEMENT
GT Biopharma, Inc.
Biotechnology
2008
BRISTOL CAPITAL ADVISORS, LLC
GT Biopharma, Inc.
Biotechnology
2008
BRISTOLCAPITAL ADVISORS, LLC
GT Biopharma, Inc.
Biotechnology
2008
Exhibit 10.1
GT Biopharma, Inc.
Biotechnology
OR
2005